Shows
Cancer ABCs From Surviving To Thriving - How to Thrive with CancerUsing the Oncotype DX Genomic Prostate Score to Decide if You Are A Candidate for Active SurveillanceWritten Transcript at:https://www.cancerabcs.org/transcript-oncotype-prostate-sore-and-active-surveillanceMr. Anson Tharayanil, a Medical Science Liaison from Genomic Health rejoins Joel Nowak from Cancer ABCs to talk about another test for men diagnosed with low or favorable medium risk prostate cancer, the Oncotype DX Genomic Prostate Score.The test should be used along side the traditional measures we use like biopsy Gleason Grade and scans to help a man decide if he is a good candidate for Active Surveillance (AS) as opposed to having surgical or a radiation intervention. Biopsies only sample 1% of a...2019-07-1921 minCancer ABCs From Surviving To Thriving - How to Thrive with CancerUsing The Genomic Health ARV-7 Test When You Are Taking Xtandi, Zytiga or ErleadaWritten Transcript at:https://www.cancerabcs.org/transcript-using-the-genomic-health-arv-7-test-when-you-arev-aking-xtandi-zytiga-or-erleadaIn this podcast Anson Tharayanil, a Meical Science Liaison from Genomic Health, Inc. talks with Joel Nowak about their test, the Oncotype DX ARV-7 Nucleus Detect Test for men with castrate resistant metastatic prostate cancer. The test is used to determine if the second line hormone therapies like Xtandi, Zytiga and Erleada will be an effective treatment for men who have the diagnosis of prostate cancer that has left the gland (if they have metastases) and are no longer responding to the first line hormone (A...2019-07-0328 min